BioSpace News Archive

Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that preclinical data from the Company’s CNTY-101 program and CAR-iT platform will be presented in two posters at the 63rd American Society of Hematology Annual Meeting & Exposition, on December 11-14, 2021 in Atlanta, Georgia and virtually.

Agios Pharmaceuticals, Inc. announced that a broad set of clinical and translational data from its genetically defined disease programs in chronic hemolytic anemias, including pyruvate kinase deficiency, thalassemia and sickle cell disease, will be presented at the American Society of Hematology Annual Meeting & Exposition, to be held Dec. 11-14, 2021, virtually and in person in Atlanta.

Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, announced that it has granted restricted stock unit awards to two employees, none of whom are executive officers, as an inducement for them to accept employment with Surgalign, and representing the right to receive, in the aggregate, up to 177,027 shares of Surgalign common stock.

Freeline Therapeutics Holdings plc today announced that data from its long-term follow-up study to its Phase 1/2 B-AMAZE clinical trial of FLT180a for the treatment of hemophilia B will be presented at the 63rd American Society of Hematology

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer announced that it will present updated data from its blood cancer portfolio at the 63rd Annual Meeting of the American Society of Hematology taking place December 11 – 14, 2021.

Viracta Therapeutics, Inc. today announced the acceptance of two abstracts for oral presentation and one for a poster presentation at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting, which will be held from December 11-14, 2021, both in Atlanta, Georgia and virtually.

Aruvant Sciences announced that an abstract demonstrating the clinical benefit of the company’s lead product candidate ARU-1801 has been published online and will be the subject of a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

Gracell Biotechnologies Inc. announced preclinical data for GC502, an allogeneic chimeric antigen receptor T cell therapy for the treatment of B-cell malignancies, will be presented as a virtual poster at the 63rd American Society of Hematology Annual Meeting and Exposition as part of the “Cellular Immunotherapies: Basic and Translational” session on December 11, 2021 from 5:30 p.m.-7:30 p.m..

AbbVie will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology Annual Meeting in Atlanta, Georgia.

bluebird bio, Inc. announced that new data from its lentiviral vector gene addition programs for patients with β-thalassemia who require regular red blood cell transfusions and sickle cell disease will be presented at the 63rd American Society of Hematology Annual Meeting and Exposition, taking place December 11-14, 2021, at the Georgia World Congress Center in Atlanta, Georgia, and virtually.